BIOTIME--EIN KAUF? - 500 Beiträge pro Seite

[gerdass]

ZUR HP VON BIOTIME
http://www.biotimeinc.com/

Marktkapitalisierung 60,67 Mio.

[gerdass]

AUCH HIER IST DER TREND ZU ERKANNEN

[gerdass]

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[gerdass]

To the Honorable Barack H. Obama, President-Elect of the
United States
Ten years ago the discovery of human embryonic stem cells
touched off one of the most controversial and yet promising
technologies of our generation. These cells likely possess the
capacity to differentiate into all of the cell types of the human body.
They offer possibilities to produce new lifesaving therapies by
supplying heart muscle cells, dopaminergic neurons, and pancreatic
cells that could be used to rebuild the heart after a heart attack, the
brain of a patient with Parkinson’s disease, or glucose regulation in
children with diabetes. The landscape of diseases and medical
research problems potentially benefiting from this research is broad
and significant. However, for the last 10 years research in this field
has been slowed by restrictive federal funding policies and
consequent reservations in the private sector about committing
investment dollars in a field where the United States has no clear
policy.
In the coming decade our nation is facing significant economic
and social challenges, not the least of which are strains on our health
care system arising from the mounting health care costs associated
with the aging of the post WWII baby boom generation. As reported
by analysts associated with the stem cell initiative in California
(http://www.cirm.ca.gov/pub/pdf/EcoEval_091008_rpt.pdf) research
monies spent now to address novel and powerful new therapeutic
modalities such as those arising from stem cell research have
numerous potential economic benefits for the United States, leading
to advances in our understanding of not only methods of fashioning
valuable new therapies from stem cells but also deep insights into
cancer stem cells, developmental disorders, and the networks that
regulate gene expression.
While we recognize that legitimate ethical issues have been
raised by this research, it is important to understand that novel
technologies show the potential to produce “induced pluripotent stem
(iPS) cells” wherein no embryos or egg cells are utilized. In addition,
the majority of US citizens support hES cell research where the
embryos were destined to be discarded. Lastly, for the past 40 years
many of the common human virus vaccines including those directed
to measles, rubella, hepatitis A, rabies and poliovirus have been
derived from cells derived from human aborted fetal tissue, and these
vaccines have provided benefit to tens of millions of people. Thus,
there is a clear path to advancing the field of regenerative medicine in
a manner consistent with the values of the majority of Americans.
In 1961 President Kennedy displayed the vision of his
generation by focusing the financial resources of the United States
toward landing a man on the moon within a decade. A similar
visionary program in our time should be a 10-year program involving
academia and industry with a goal to translate the discovery of
human embryonic stem cells into actual safe and efficacious
therapies to save human life. We encourage you to make this a
priority for your administration. We could clearly demonstrate the
humanitarian spirit of our country by leading the world in applying the
best of mankind’s technologies in the alleviation of human suffering
including the millions of American patients who so desperately need
them.
Yours respectfully,
Kenneth J. Arrow*
Stanford University
Nobel Laureate, Economics, 1972
Baruj Benacerraf*
Dana-Farber Cancer Institute
Nobel Laureate, Physiology or Medicine, 1980
Robert N. Butler+
International Longevity Center
Founding Director, National Institute on Aging, National Institutes of Health
Mario R. Capecchi*
Howard Hughes Medical Institute, University of Utah School of Medicine
Nobel Laureate, Physiology or Medicine, 2007
Elias James Corey*
Harvard University
Nobel Laureate, Chemistry, 1990
Edmond H. Fischer*
University of Washington
Nobel Laureate, Physiology or Medicine, 1992
Robert W. Fogel*
University of Chicago Booth School of Business
Nobel Laureate, Economics, 1993
Corey Goodman+
Member National Academy of Sciences
Ronald M. Green+
Ethics Institute, Dartmouth College
Roger Guillemin*
Salk Institute for Biological Studies
Nobel Laureate, Physiology or Medicine, 1977
Herbert A. Hauptman*
Hauptman-Woodward Medical Research Institute, SUNY at Buffalo
Nobel Laureate, Chemistry, 1985
Leonard Hayflick+
University of California, San Francisco
James J. Heckman*
University of Chicago
Nobel Laureate, Economics, 2000
Dudley R. Herschbach*
Harvard University
Nobel Laureate, Chemistry, 1986
William Lipscomb*
Harvard University
Nobel Laureate, Chemistry, 1976
Marshall W. Nirenberg*
National Heart, Lung & Blood Institute, National Institutes of Health
Nobel Laureate, Physiology or Medicine, 1968
Eric S. Maskin*
Institute for Advanced Study
Nobel Laureate, Economics, 2007
George A. Olah*
University of Southern California
Nobel Laureate, Chemistry, 1994
Richard J. Roberts*
New England Biolabs
Nobel Laureate, Physiology or Medicine, 1993
Richard R. Schrock*
Massachusetts Institute of Technology
Nobel Laureate, Chemistry, 2005
Phillip A. Sharp*
Massachusetts Institute of Technology
Nobel Laureate, Physiology or Medicine, 1993
Hamilton O. Smith*
J. Craig Venter Institute
Noble Laureate, Physiology or Medicine, 1978
Robert M. Solow*
Massachusetts Institute of Technology
Nobel Laureate, Economics, 1987
James D. Watson*
Cold Spring Harbor Laboratory
Nobel Laureate, Physiology or Medicine, 1962
Michael D. West+
BioTime, Inc.
Robert W. Wilson*
Harvard-Smithsonian Center for Astrophysics
Nobel Laureate, Physics, 1978
+ Corresponding Author
* Nobel Laureate

[seblas]

Antwort auf Beitrag Nr.: 36.519.089 von gerdass am 05.02.09 14:35:49

BioTime, Inc. (BTIM.OB) 2.55 sehr schwach ... top

[gerdass]

Antwort auf Beitrag Nr.: 36.519.433 von seblas am 05.02.09 15:08:21

ABWARTEN; WIE ES WEITER GEHEN WIRD:

[h-level]

- fast schon wieder zu stark überkauft :/
- MACD wird wohl schon bald wieder kreuzen (03/09)
- Aktie wird kaum gehandelt (B/Germ.)
- hohe Volatilität

--> eher was für Zocker?!
--> überzeugt mich pers. nicht

[gerdass]

[gerdass]

[Caravest]

Antwort auf Beitrag Nr.: 36.519.859 von gerdass am 05.02.09 15:50:35

stimme h-level zu. Ich selber würde jetzt nicht einsteigen, vor allem deshalb, weil praktisch kein Handel stattfindet.

[gerdass]

Antwort auf Beitrag Nr.: 36.520.203 von Caravest am 05.02.09 16:25:06

Ich bin hier nur mit ein paar Tausend Dollar drin und erhoffe mir auf eine längere Sicht gut investiert zu sein.
Ich schließe nicht aus, das auf Grund der MK. u. des Kurses es sich ausnahmsweise für OTC Verhältnisse um Qualität handeln kann.
Mit Geduld kann das durchaus was werden.
Im Pluß bin ich schon ganz schön.

[Caravest]

Antwort auf Beitrag Nr.: 36.520.463 von gerdass am 05.02.09 16:48:50

Wie bei jedem Investment:
viel Erfolg!

[gerdass]

Antwort auf Beitrag Nr.: 36.520.203 von Caravest am 05.02.09 16:25:06

Das kann ich so nicht stehen lassen.
Am gestriegen Handelstag wurden 318.016,17 Dollar gehandelt.
Wenn Qualität am steigen ist, sieht das zunächst erst mal sehr moderat aus.

[gerdass]

[gerdass]

Schaun mer mal, was heuer so geht.

[gerdass]

http://www.biotimeinc.com/
spannung pur

[gerdass]

mal schauen, was hute so geht

[gerdass]

Antwort auf Beitrag Nr.: 36.520.644 von Caravest am 05.02.09 17:02:02

[gerdass]

Antwort auf Beitrag Nr.: 36.519.757 von h-level am 05.02.09 15:41:39

........

[gerdass]

Antwort auf Beitrag Nr.: 36.520.644 von Caravest am 05.02.09 17:02:02

Wer hätte das gedacht

hättest du auch drauf kommen können
was hier zu erwarten ist

[gerdass]

na

[gerdass]

das gibt es eher selten an der OTC

[dottore]

wie hoch soll der Wert denn steigen? Ist doch schon ein Tenbagger

[gerdass]

[dottore]

es macht mich ganz krank, hier nicht dabei zu sein
ich versterbe noch vor Neid! Schon seit 2,10 Euro schaue ich zu und trau mich nicht.
Und jetzt erst recht nicht!
Übrigens steigen die auch deshalb, weil es noch Warrants gibt, die gleichzeitig und doppelt so stark steigen. Leider weiß ich aber nicht wie lange die laufen. .....
dann kommt der crash - vielleicht

[gerdass]

803.757 Volumen

[gerdass]

[gerdass]

[sven641]

Kann mich mal jemand ins Bild setzen was bei der Aktie abgeht ?

Scheint bis auf den Rücksetzter von 7 auf 4 nur eine Richtung zu kennen

[dottore]

also die Warrants haben eine Laufzeit bis Dezember 2010.
Kürzel BTIMW, kann z. B. bei Consors nicht gehandelt werden, weil unbekannt. Müßte man wohl per Fax ordern. ...

Charttechnisch ist ein NIveu erreicht, wo keiner mehr einsteigt und keiner Kursrückgänge hinnehmen will. Also eine Seitwärtsbewegung ist zu erwarten, wahrscheinlich bis sich der Kurs mit der 200Tage-Linie kreuzt. Da das noch in diesem Jahr passiert, wird bei gutem Börsenklima die nächste Ralley starten. Bis dahin sollte man wissen, wie man an die Warrants ran kommt (zu vernünftigen Bedingungen)
Bin dankbar für hilfreiche Info

[sven641]

New BioTime Subsidiary, OncoCyte Corporation, Receives $2
2009-10-15 21:00:01.150 GMT

New BioTime Subsidiary, OncoCyte Corporation, Receives $2 Million Equity
Financing to Develop Cancer Treatments Using Stem Cell Technology

Agreement Provides Investor Option for an Additional $2 Million Investment
Within Six Months

Business Wire

ALAMEDA, Calif. -- October 15, 2009

BioTime, Inc. (OTCBB:BTIM) announced today that it has organized a new
subsidiary, OncoCyte Corporation, for the purpose of developing novel
therapeutics for the treatment of cancer based on stem cell technology.
BioTime will license certain technology to the new company restricted to the
field of cell-based cancer therapies, including early patent filings on
targeting stem cells to malignant tumors. A private investor has purchased
3,000,000 common shares of OncoCyte for $2 million, representing an initial
15% stake in the new company, and the investor has the option of purchasing an
additional 3,000,000 common shares for $2 million on or before April 15, 2010,
based on an agreed initial market cap of approximately $15,000,000.

OncoCyte’s new therapeutic strategy and goal will be to utilize human
embryonic stem cell technology to create genetically modified stem cells
capable of homing to specific malignant tumors while carrying genes that can
cause the destruction of the cancer cells. This therapeutic use of human
embryonic stem cells differs from most proposed industrial uses of stem cell
technology in that OncoCyte’s goal is not the stable engraftment of the cells
to regenerate tissue function, but rather a use of the unique properties of
stem cells as a tool to eliminate malignant cells.

“Cancer is the second leading cause of death in the United States,” said David
Jin, M.D., Ph.D., OncoCyte’s new Chief Medical Officer. “The ability of human
embryonic stem cells to be genetically modified and then transformed into any
of the cells of the human body may provide a cell-based strategy to targeting
and destroying particularly intractable forms of human cancer, such as
metastatic breast, lung, prostate, cervical, pancreatic tumors.”

“There is a wide array of novel and potentially valuable therapies possible
with human embryonic stem cell technology,” said Michael West, Ph.D.,
BioTime’s CEO. “OncoCyte is part of BioTime’s strategy to create value for our
shareholders by forming subsidiaries focused on specific therapeutic
applications of stem cell technologies. We previously organized our first
subsidiary, Embryome Sciences, Inc., to bring BioTime relatively near-term
revenues through the sale of our products into the research market. Embryome
Sciences will co-market certain stem cell research products with Millipore
Corporation. Similarly, our formation of BioTime Asia offers the possibility
of accelerating the commercialization of diverse therapeutic and research
applications of stem cells in the People’s Republic of China.”

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. BioTime
develops and markets research products in the field of stem cells and
regenerative medicine through its wholly owned subsidiary Embryome Sciences,
Inc. In addition to its stem cell products, BioTime markets blood plasma
volume expanders and related technology for use in surgery, emergency trauma
treatment, and other applications. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,”) should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange Commission filings.
The company disclaims any intent or obligation to update these forward-looking
statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0

Contact:

BioTime, Inc.
Judith Segall, 510-521-3390 ext. 301
[e-mail]

-0- Oct/15/2009 21:00 GMT

[gerdass]

[gerdass]

Antwort auf Beitrag Nr.: 38.215.207 von sven641 am 20.10.09 17:15:16

schaut gut aus

[sven641]

irgendwelche Neuigkeiten ?

[Bronto99]

Antwort auf Beitrag Nr.: 38.669.931 von sven641 am 05.01.10 18:11:12

Keine Neuigkeiten, nur ein paar Informationen:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9M…

[sven641]

Danke,das kannte ich schon

[sven641]

Scheint jetzt zu laufen......

[sven641]

die biotechs gehen ja alle ab im Moment

ich glaube,dass die großen wie Pfizer nicht sehr viel
in der Pipeline haben und deswegen den einen oder anderen kleinen kaufen werden

[sven641]

Neue Ideen zu Biotime ?

[gerdass]

BIOTIME--EIN KAUF?

[sven641]

BioTime Announces Addition of New Stem Cell Lines to Its
2010-07-21 16:52:00.351 GMT

BioTime Announces Addition of New Stem Cell Lines to Its Product Portfolio

Business Wire

ALAMEDA, Calif. -- July 21, 2010

BioTime, Inc. (AMEX:BTIM) announced today that on August 1, 2010 the Company
will be offering for sale 21 new stem cell products for research use only.
These products will include the novel stem cell lines: E120 expressing the
gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8,
SM22, and Z1, full properties of which will be disclosed on product launch,
along with differentiation kits and media for the culture of each line.
BioTime CEO Dr. Michael West will discuss these new products as part of his
presentation today on “Regenerative Medicine: Finding Opportunity in a
Scientific Revolution” at the Agora Financial Investment Symposium 2010, July
20-23, at the Fairmont Hotel Vancouver. Additional information about the
products may be found online at www.embryome.com/products.htm beginning August
1, 2010.

Dr. West’s presentation will address the state of the regenerative medicine
industry in addition to the update on BioTime’s 2010 product portfolio aimed
at the near-term research market. Dr. West's presentation will be available
online at www.biotimeinc.com.

The annual symposium this year by Agora Financial, LLC, will focus on the
impact of the current economic and political climate on investment strategies.
Agora Financial is an independent provider of economic forecasting and
financial research.

[gerdass]

http://www.advfn.com/p.php?pid=staticchart&s=NB^BTIM&p=0&t=2…

[gerdass]

eröffnet am:
05.02.09 14:35:49 von: gerdass

[gerdass]

[sven641]

geht ja gut ab heute

[sven641]

wie seht ihr die Sache mit den Warrants ?

[dottore]

Zitat von sven641: wie seht ihr die Sache mit den Warrants ?

sollen die Warrents nicht in den nächsten Wochen auslaufen? Dann müßte doch ein Einbruch zu erwarten sein, es sei denn es kommen neue Warrants und die Leier geht von vorne los.

Könnte mir beide Szenarien vorstellen.

Jedenfalls sagt mir mein Bauchgefühl, dass eine große Bewegung ansteht , und da ich nicht investiert bin, hoffe ich auf den Rutsch um günstig rein zu kommen.

[sven641]

Da ist er,der Rutsch

[dottore]

Antwort auf Beitrag Nr.: 40.947.594 von sven641 am 29.01.11 09:07:09

und ich habe ihn genutzt. in zu 7,90 $ rein und prompt mit einem kleinen Verlust angefangen.

Ich war schon mal investiert und habe einen Teil des rasanten Anstiegs mitgenommen. Jetzt sollten wir wieder einen Anstieg sehen

BioTime Signs Definitive Agreement To Merge Glycosan BioSystems With OrthoCyte

[dottore]

und heute ist es endlich so weit, oder nur charttechnische Korrektur?

Immerhin 12-15 % heute und zwar GRÜN !

[sven641]

Die Nachrichten in der letzten Zeit waren alle positiv.

Der Move heute ist zurückzuführen auf Artikel von Pat Cox.

Hoffe es geht weiter

[dottore]

nach dem relativ guten Verlauf der letzten Tage, die die Schwächephase sicher beendet hat, kommt erst mal etwas Luft holen.

Ich denke, dass dieser Wert bei ruhiger Marktlage einen größeren Kursanstieg vor sich hat.

Bin gespannt auf die nächste Aquisition

[dottore]

kurz nach meinem posting ging die Aktie ja recht gut ab um dann kontinuierlich wieder zu fallen, im April sogar beschleunigt. Die Quartalszahlen waren dabei gar nicht mal als schlecht zu bezeichnen. Über 60 Cent cash/Aktie und Totalverschuldung 7 Cent/Aktie

Allerdings sind die Umsätze stagniert auf Viorjahresniveau

und doch sollte ein Knaller erfolgen. Als Großaktionär von Cell Cure Neurosciences (immerhin 53,5 % der Aktien), wurde dieVerpartnerung mit Teva an Opregen zur Behandlung der Maculadegeneration schon vor 1/2 Jahr bekannt gegeben ...